LB Pharmaceuticals Inc develops novel therapies for neuropsychiatric diseases, led by LB-102, an oral investigational small molecule and benzamide antipsychotic candidate for schizophrenia, bipolar depression and adjunctive major depressive disorder. Company news frequently centers on LB-102 clinical data, peer-reviewed publications, medical-conference presentations and trial-program updates across schizophrenia and mood-disorder indications.
Other recurring updates include financial results, capital-raising activity, board and executive appointments, Nasdaq inducement grants and healthcare-conference participation. These announcements frame the company's single-segment biopharmaceutical model around clinical development, financing needs and governance as it advances LB-102.
LB Pharmaceuticals (Nasdaq: LBRX) reported that, based on updated enrollment projections, it now expects topline results from the pivotal Phase 3 NOVA-2 trial of LB-102 in schizophrenia in the first half of 2027, earlier than its prior guidance of the second half of 2027. A pre-NDA meeting with the FDA is expected to be scheduled in the second half of 2027.
NOVA-2 is a multi-center, randomized, double-blind, placebo-controlled Phase 3 study designed to enroll about 460 patients across 25 U.S. sites. According to LB Pharmaceuticals, faster-than-expected enrollment reflects execution strength and interest in LB-102. The company also states it is well capitalized, with a cash runway into Q2 2029, covering multiple planned readouts, including Phase 2 data in bipolar depression in the first quarter of 2028 and in adjunctive major depressive disorder in the first half of 2029.
LB Pharmaceuticals (Nasdaq: LBRX) granted an equity inducement award to its new Senior Vice President, Clinical Operations, Christopher Zergebel, on July 10, 2026. The award consists of an option to purchase 75,000 shares of common stock, granted outside of but subject to the 2025 Equity Incentive Plan under Nasdaq Listing Rule 5635(c)(4).
The stock option has a 10-year term and an exercise price of $32.95, equal to the closing price on the grant date. It vests over four years: 25% after one year and the remaining shares in equal monthly installments over the following three years, contingent on continuous service.
LB Pharmaceuticals (Nasdaq:LBRX) appointed Christopher Zergebel as Senior Vice President, Clinical Operations. He brings over 25 years of global development operations experience across clinical operations, data management, and project and portfolio management.
He will support LB-102 Phase 3 schizophrenia and Phase 2 bipolar depression trials, plus a planned Phase 2 adjunctive major depressive disorder study.
LB Pharmaceuticals (Nasdaq:LBRX) will participate in two June 2026 investor conferences. Executives present at the Jefferies Global Healthcare Conference on June 4, 2026 at 2:35 p.m. ET and at the H.C. Wainwright 7th Annual Neuro Perspectives Hybrid Conference on June 16, 2026.
Webcasts and replays will be accessible on the company’s Investors > Events webpage.
LB Pharmaceuticals (Nasdaq:LBRX) reported Q1 2026 results and a clinical and corporate update. The company initiated the pivotal Phase 3 NOVA-2 trial in schizophrenia, Phase 2 ILLUMINATE-1 in bipolar 1 depression, and a 52-week NOVA-3 safety study, and published Phase 2 NOVA-1 data in JAMA Psychiatry.
LB Pharmaceuticals closed a $100 million private placement, with net proceeds of $93.8 million, and plans a Phase 2 adjunctive MDD trial in early 2027. Q1 2026 R&D expenses were $14.6 million and G&A expenses $7.5 million, leading to a $19.1 million net loss. Cash, cash equivalents, and marketable securities totaled $365.6 million, expected to fund operations into Q2 2029.
LB Pharmaceuticals (Nasdaq: LBRX) announced publication in JAMA Psychiatry of Phase 2 NOVA-1 results for LB-102 in adults with acute schizophrenia. The trial showed statistically significant benefit versus placebo, rapid onset at week 1, sustained effect at endpoint, and a favorable safety profile. The pivotal Phase 3 NOVA-2 trial (approx. 460 patients, 6 weeks, ~25 U.S. sites) is ongoing with topline data expected in 2H 2027.
LB Pharmaceuticals (Nasdaq: LBRX) announced that CEO Heather Turner will present at the 25th Annual Needham Virtual Healthcare Conference on April 16, 2026 at 11:45 a.m. ET. A live webcast and replay will be available on the company’s Investors > Events webpage.
The presentation provides an opportunity to hear management discuss business progress and strategy for LB Pharmaceuticals' late-stage neuropsychiatric therapy programs.
LB Pharmaceuticals (Nasdaq: LBRX) presented new Phase 2 NOVA-1 analyses at SIRS on March 27, 2026, showing LB-102 produced a statistically significant, dose-dependent improvement in global cognition that was primarily a direct drug effect rather than secondary to overall symptom change.
LB-102 is a once-daily oral selective D2/D3/5HT7 antagonist that showed benefit versus placebo across PANSS Marder factors, rapid onset at week 1, sustained effects through endpoint, and a favorable safety profile with low EPS, minimal sedation, and few GI side effects. The company plans cognition as a secondary endpoint in pivotal NOVA-2 and other trials.
LB Pharmaceuticals (Nasdaq: LBRX) reported positive Phase 2 results for LB-102 in acute schizophrenia and advanced LB-102 into late-stage development, initiating a Phase 3 NOVA-2 trial (topline H2 2027) and a Phase 2 bipolar depression trial (ILLUMINATE-1; topline Q1 2028).
The company completed an IPO raising $327.8 million, added a $100 million private placement, and reported cash, cash equivalents, and investments of $295.2 million as of December 31, 2025—expected to fund operations into Q2 2029.
LB Pharmaceuticals (Nasdaq: LBRX) initiated its pivotal Phase 3 trial NOVA-2 of LB-102 for schizophrenia on March 25, 2026. NOVA-2 will randomize ~460 patients 1:1:1 to 50 mg, 100 mg, or placebo for six weeks; primary endpoint is change in PANSS total score at Week 6.
Secondary endpoints include negative symptoms, cognitive performance, CGI-S, Marder factors, and PSP. An ~900-patient open-label extension is planned. Topline data are expected in 2H 2027; a pre-NDA meeting with FDA is expected if results are positive.